Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights, 2017

  • ID: 4037861
  • Drug Pipelines
  • 60 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
“Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights, 2017” provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Lymphoma Kinase (ALK) Inhibitors. The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anaplastic Lymphoma Kinase (ALK) Inhibitors. This report also assesses the Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up - to - date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:
  • The report provides competitive pipeline landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Anaplastic Lymphoma Kinase (ALK) Inhibitors and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Delivery Time: 2 Working Days.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Anaplastic Lymphoma Kinase (ALK) Inhibitors Overview
Anaplastic Lymphoma Kinase (ALK) Inhibitors Disease Associated
Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Therapeutics
Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics under Development by Companies
Anaplastic Lymphoma Kinase (ALK) Inhibitors Filed and Phase III Products
Comparative Analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors Phase II Products
Comparative Analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors Phase I and IND Filed Products
Comparative Analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Discontinued Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Dormant Products
Companies Involved in Therapeutics Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapy Area, 2017
Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors, 2017
Number of Products under Development by Companies
Comparative Analysis by Filed and Phase III Products, 2017
Comparative Analysis Phase II Products, 2017
Comparative Analysis Phase I and IND Filed Products, 2017
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
Drug Candidates Profiles
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Monotherapy Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Combination Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Route of Administration
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Route of Administration
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics - Discontinued Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics - Dormant Products
Products under Development by Companies, 2017

List of Figures
Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapy Area, 2017
Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors, 2017
Filed and Phase III Products, 2017
Phase II Products, 2017
Phase I and IND Filed Products, 2017
Discovery and Pre-Clinical Stage Products, 2017
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Monotherapy Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Combination Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Route of Administration
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Route of Administration
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Molecule Type
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll